Global Genital Warts Treatment Market
Global Genital Warts Treatment Market

Genital Warts Treatment Comprehensive Study by Drug Type (Podophyllotoxin, Imiquimod, Sinecatechins, Podophyllin, 5-FU), Mechanism of Action (Immunomodulators, Immunomodulators; Virus Internalization Inhibitors, DNA Helicase-Primase Inhibitors, Immunostimulants), Stage (Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III, By Application, Patient, Physician) Players and Region - Global Market Outlook to 2026

Genital Warts Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 218 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Genital warts, also known as condylomata acuminate, are warts that appear as small bumps on or near the genitals or anus. Physical examination, which includes an examination of the vaginal and rectal areas, may usually detect genital warts. Topical drugs like creams and ointments, as well as surgical techniques like freezing, excision, and laser removal, are all used to treat genital warts. Over the projected period, the global genital warts treatment market is expected to rise due to an increase in the prevalence of (HPV) infection, which is the cause of the formation of genital warts.This growth is primarily driven by The market is being driven by an increase in the prevalence of warts and HPV infections. People who have a weaker immune system as a result of an organ transplant, catastrophic diseases like cancer or AIDS, or atopic conditions are more likely to acquire warts. and As a result, as the number of persons diagnosed with cancer rises, so does the prevalence of warts, driving the market..

Globally, a noticeable market trend is evident Government and nongovernment financing is supporting cancer vaccine research, based on the efficacy of vaccinations to prevent HPV-related malignancies and lower the cancer burden.. Major Players, such as Merck & co. Inc. (United States), Teva Pharmaceuticals Industries Ltd. (Israel), Pfizer (United States), Seqirus (United Kingdom), Sanofi (France), Novan Inc (United States), Mylan NV (United States), Verrica Pharmaceuticals (United States), Aresus Pharma GmbH (Germany) and 3M (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In April 2020 Orgenesis Acquired Tamir Biotechnology for a broad spectrum of Antiviral Treatment. The human papillomavirus is TamirBio's first target (HPV). In a Phase I/II clinical research targeting genital warts caused by HPV, the company's primary asset, topical ranpirnase, was assessed. The results of the investigation showed that ranpirnase had a distinct clinical effect.
In March 2021 Torii Pharmaceutical Co. Ltd. was granted an exclusive right to develop and commercialize Verrica's pharmaceutical candidates for the treatment of molluscum contagiosum and common warts in Japan under a License Agreement.

Market Drivers
  • The market is being driven by an increase in the prevalence of warts and HPV infections. People who have a weaker immune system as a result of an organ transplant, catastrophic diseases like cancer or AIDS, or atopic conditions are more likely to acquire warts.
  • As a result, as the number of persons diagnosed with cancer rises, so does the prevalence of warts, driving the market.

Market Trend
  • Government and nongovernment financing is supporting cancer vaccine research, based on the efficacy of vaccinations to prevent HPV-related malignancies and lower the cancer burden.

Restraints
  • Despite the fact that warts are common in the general population, the diagnostic rate is still low. The low diagnosis rate of genital warts is attributed to a lack of awareness about the virus, which may stymie the market growth for genital warts treatments.

Opportunities
Due to the high incidence of genital warts in the general population and the rise of effective treatments, HPV vaccinations such as HPV4 and HPV2 may play an important role in the growth of the market.
Challenges
Some People May be Hesitant to See a Doctor to Have Genital Warts Diagnosed. and The Human Papillomavirus (HPV), Which Causes Genital Warts, Has No Cure; Therefore They May Reappear After Therapy

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Genital Warts Treatment Study Sheds Light on
— The Genital Warts Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Genital Warts Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Genital Warts Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Genital Warts Treatment Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Genital Warts Treatment Market?
Companies that are profiled in Global Genital Warts Treatment Market are Merck & co. Inc. (United States), Teva Pharmaceuticals Industries Ltd. (Israel), Pfizer (United States), Seqirus (United Kingdom), Sanofi (France), Novan Inc (United States), Mylan NV (United States), Verrica Pharmaceuticals (United States), Aresus Pharma GmbH (Germany) and 3M (United States) etc.

3. What is Genital Warts Treatment Market?
Genital warts, also known as condylomata acuminate, are warts that appear as small bumps on or near the genitals or anus. Physical examination, which includes an examination of the vaginal and rectal areas, may usually detect genital warts. Topical drugs like creams and ointments, as well as surgical techniques like freezing, excision, and laser removal, are all used to treat genital warts. Over the projected period, the global genital warts treatment market is expected to rise due to an increase in the prevalence of (HPV) infection, which is the cause of the formation of genital warts.
Report Objectives / Segmentation Covered
By Drug Type
  • Podophyllotoxin
  • Imiquimod
  • Sinecatechins
  • Podophyllin
  • 5-FU

By Mechanism of Action
  • Immunomodulators
  • Immunomodulators; Virus Internalization Inhibitors
  • DNA Helicase-Primase Inhibitors
  • Immunostimulants

By Stage
  • Discovery
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • By Application
  • Patient
  • Physician

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The market is being driven by an increase in the prevalence of warts and HPV infections. People who have a weaker immune system as a result of an organ transplant, catastrophic diseases like cancer or AIDS, or atopic conditions are more likely to acquire warts.
      • 3.2.2. As a result, as the number of persons diagnosed with cancer rises, so does the prevalence of warts, driving the market.
    • 3.3. Market Challenges
      • 3.3.1. Some People May be Hesitant to See a Doctor to Have Genital Warts Diagnosed.
      • 3.3.2. The Human Papillomavirus (HPV), Which Causes Genital Warts, Has No Cure; Therefore They May Reappear After Therapy
    • 3.4. Market Trends
      • 3.4.1. Government and nongovernment financing is supporting cancer vaccine research, based on the efficacy of vaccinations to prevent HPV-related malignancies and lower the cancer burden.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genital Warts Treatment, by Drug Type, Mechanism of Action, Stage and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Genital Warts Treatment (Value)
      • 5.2.1. Global Genital Warts Treatment by: Drug Type (Value)
        • 5.2.1.1. Podophyllotoxin
        • 5.2.1.2. Imiquimod
        • 5.2.1.3. Sinecatechins
        • 5.2.1.4. Podophyllin
        • 5.2.1.5. 5-FU
      • 5.2.2. Global Genital Warts Treatment by: Mechanism of Action (Value)
        • 5.2.2.1. Immunomodulators
        • 5.2.2.2. Immunomodulators; Virus Internalization Inhibitors
        • 5.2.2.3. DNA Helicase-Primase Inhibitors
        • 5.2.2.4. Immunostimulants
      • 5.2.3. Global Genital Warts Treatment by: Stage (Value)
        • 5.2.3.1. Discovery
        • 5.2.3.2. Pre-clinical
        • 5.2.3.3. IND
        • 5.2.3.4. Phase I
        • 5.2.3.5. Phase II
        • 5.2.3.6. Phase III
        • 5.2.3.7. By Application
        • 5.2.3.8. Patient
        • 5.2.3.9. Physician
      • 5.2.4. Global Genital Warts Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Genital Warts Treatment (Price)
  • 6. Genital Warts Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & co. Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharmaceuticals Industries Ltd. (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Seqirus (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novan Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan NV (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Verrica Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Aresus Pharma GmbH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. 3M (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Genital Warts Treatment Sale, by Drug Type, Mechanism of Action, Stage and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Genital Warts Treatment (Value)
      • 7.2.1. Global Genital Warts Treatment by: Drug Type (Value)
        • 7.2.1.1. Podophyllotoxin
        • 7.2.1.2. Imiquimod
        • 7.2.1.3. Sinecatechins
        • 7.2.1.4. Podophyllin
        • 7.2.1.5. 5-FU
      • 7.2.2. Global Genital Warts Treatment by: Mechanism of Action (Value)
        • 7.2.2.1. Immunomodulators
        • 7.2.2.2. Immunomodulators; Virus Internalization Inhibitors
        • 7.2.2.3. DNA Helicase-Primase Inhibitors
        • 7.2.2.4. Immunostimulants
      • 7.2.3. Global Genital Warts Treatment by: Stage (Value)
        • 7.2.3.1. Discovery
        • 7.2.3.2. Pre-clinical
        • 7.2.3.3. IND
        • 7.2.3.4. Phase I
        • 7.2.3.5. Phase II
        • 7.2.3.6. Phase III
        • 7.2.3.7. By Application
        • 7.2.3.8. Patient
        • 7.2.3.9. Physician
      • 7.2.4. Global Genital Warts Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Genital Warts Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genital Warts Treatment: by Drug Type(USD Million)
  • Table 2. Genital Warts Treatment Podophyllotoxin , by Region USD Million (2015-2020)
  • Table 3. Genital Warts Treatment Imiquimod , by Region USD Million (2015-2020)
  • Table 4. Genital Warts Treatment Sinecatechins , by Region USD Million (2015-2020)
  • Table 5. Genital Warts Treatment Podophyllin , by Region USD Million (2015-2020)
  • Table 6. Genital Warts Treatment 5-FU , by Region USD Million (2015-2020)
  • Table 7. Genital Warts Treatment: by Mechanism of Action(USD Million)
  • Table 8. Genital Warts Treatment Immunomodulators , by Region USD Million (2015-2020)
  • Table 9. Genital Warts Treatment Immunomodulators; Virus Internalization Inhibitors , by Region USD Million (2015-2020)
  • Table 10. Genital Warts Treatment DNA Helicase-Primase Inhibitors , by Region USD Million (2015-2020)
  • Table 11. Genital Warts Treatment Immunostimulants , by Region USD Million (2015-2020)
  • Table 12. Genital Warts Treatment: by Stage(USD Million)
  • Table 13. Genital Warts Treatment Discovery , by Region USD Million (2015-2020)
  • Table 14. Genital Warts Treatment Pre-clinical , by Region USD Million (2015-2020)
  • Table 15. Genital Warts Treatment IND , by Region USD Million (2015-2020)
  • Table 16. Genital Warts Treatment Phase I , by Region USD Million (2015-2020)
  • Table 17. Genital Warts Treatment Phase II , by Region USD Million (2015-2020)
  • Table 18. Genital Warts Treatment Phase III , by Region USD Million (2015-2020)
  • Table 19. Genital Warts Treatment By Application , by Region USD Million (2015-2020)
  • Table 20. Genital Warts Treatment Patient , by Region USD Million (2015-2020)
  • Table 21. Genital Warts Treatment Physician , by Region USD Million (2015-2020)
  • Table 22. South America Genital Warts Treatment, by Country USD Million (2015-2020)
  • Table 23. South America Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 24. South America Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 25. South America Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 26. Brazil Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 27. Brazil Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 28. Brazil Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 29. Argentina Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 30. Argentina Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 31. Argentina Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 32. Rest of South America Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 33. Rest of South America Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 34. Rest of South America Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 35. Asia Pacific Genital Warts Treatment, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 37. Asia Pacific Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 38. Asia Pacific Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 39. China Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 40. China Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 41. China Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 42. Japan Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 43. Japan Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 44. Japan Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 45. India Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 46. India Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 47. India Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 48. South Korea Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 49. South Korea Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 50. South Korea Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 51. Taiwan Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 52. Taiwan Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 53. Taiwan Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 54. Australia Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 55. Australia Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 56. Australia Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 60. Europe Genital Warts Treatment, by Country USD Million (2015-2020)
  • Table 61. Europe Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 62. Europe Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 63. Europe Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 64. Germany Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 65. Germany Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 66. Germany Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 67. France Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 68. France Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 69. France Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 70. Italy Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 71. Italy Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 72. Italy Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 73. United Kingdom Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 74. United Kingdom Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 75. United Kingdom Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 76. Netherlands Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 77. Netherlands Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 78. Netherlands Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 79. Rest of Europe Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 80. Rest of Europe Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 81. Rest of Europe Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 82. MEA Genital Warts Treatment, by Country USD Million (2015-2020)
  • Table 83. MEA Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 84. MEA Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 85. MEA Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 86. Middle East Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 87. Middle East Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 88. Middle East Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 89. Africa Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 90. Africa Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 91. Africa Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 92. North America Genital Warts Treatment, by Country USD Million (2015-2020)
  • Table 93. North America Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 94. North America Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 95. North America Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 96. United States Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 97. United States Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 98. United States Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 99. Canada Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 100. Canada Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 101. Canada Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 102. Mexico Genital Warts Treatment, by Drug Type USD Million (2015-2020)
  • Table 103. Mexico Genital Warts Treatment, by Mechanism of Action USD Million (2015-2020)
  • Table 104. Mexico Genital Warts Treatment, by Stage USD Million (2015-2020)
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Genital Warts Treatment: by Drug Type(USD Million)
  • Table 116. Genital Warts Treatment Podophyllotoxin , by Region USD Million (2021-2026)
  • Table 117. Genital Warts Treatment Imiquimod , by Region USD Million (2021-2026)
  • Table 118. Genital Warts Treatment Sinecatechins , by Region USD Million (2021-2026)
  • Table 119. Genital Warts Treatment Podophyllin , by Region USD Million (2021-2026)
  • Table 120. Genital Warts Treatment 5-FU , by Region USD Million (2021-2026)
  • Table 121. Genital Warts Treatment: by Mechanism of Action(USD Million)
  • Table 122. Genital Warts Treatment Immunomodulators , by Region USD Million (2021-2026)
  • Table 123. Genital Warts Treatment Immunomodulators; Virus Internalization Inhibitors , by Region USD Million (2021-2026)
  • Table 124. Genital Warts Treatment DNA Helicase-Primase Inhibitors , by Region USD Million (2021-2026)
  • Table 125. Genital Warts Treatment Immunostimulants , by Region USD Million (2021-2026)
  • Table 126. Genital Warts Treatment: by Stage(USD Million)
  • Table 127. Genital Warts Treatment Discovery , by Region USD Million (2021-2026)
  • Table 128. Genital Warts Treatment Pre-clinical , by Region USD Million (2021-2026)
  • Table 129. Genital Warts Treatment IND , by Region USD Million (2021-2026)
  • Table 130. Genital Warts Treatment Phase I , by Region USD Million (2021-2026)
  • Table 131. Genital Warts Treatment Phase II , by Region USD Million (2021-2026)
  • Table 132. Genital Warts Treatment Phase III , by Region USD Million (2021-2026)
  • Table 133. Genital Warts Treatment By Application , by Region USD Million (2021-2026)
  • Table 134. Genital Warts Treatment Patient , by Region USD Million (2021-2026)
  • Table 135. Genital Warts Treatment Physician , by Region USD Million (2021-2026)
  • Table 136. South America Genital Warts Treatment, by Country USD Million (2021-2026)
  • Table 137. South America Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 138. South America Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 139. South America Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 140. Brazil Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 141. Brazil Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 142. Brazil Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 143. Argentina Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 144. Argentina Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 145. Argentina Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 146. Rest of South America Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 147. Rest of South America Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 148. Rest of South America Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 149. Asia Pacific Genital Warts Treatment, by Country USD Million (2021-2026)
  • Table 150. Asia Pacific Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 151. Asia Pacific Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 152. Asia Pacific Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 153. China Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 154. China Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 155. China Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 156. Japan Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 157. Japan Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 158. Japan Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 159. India Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 160. India Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 161. India Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 162. South Korea Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 163. South Korea Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 164. South Korea Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 165. Taiwan Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 166. Taiwan Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 167. Taiwan Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 168. Australia Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 169. Australia Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 170. Australia Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 171. Rest of Asia-Pacific Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 172. Rest of Asia-Pacific Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 173. Rest of Asia-Pacific Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 174. Europe Genital Warts Treatment, by Country USD Million (2021-2026)
  • Table 175. Europe Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 176. Europe Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 177. Europe Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 178. Germany Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 179. Germany Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 180. Germany Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 181. France Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 182. France Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 183. France Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 184. Italy Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 185. Italy Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 186. Italy Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 187. United Kingdom Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 188. United Kingdom Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 189. United Kingdom Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 190. Netherlands Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 191. Netherlands Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 192. Netherlands Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 193. Rest of Europe Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 194. Rest of Europe Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 195. Rest of Europe Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 196. MEA Genital Warts Treatment, by Country USD Million (2021-2026)
  • Table 197. MEA Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 198. MEA Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 199. MEA Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 200. Middle East Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 201. Middle East Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 202. Middle East Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 203. Africa Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 204. Africa Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 205. Africa Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 206. North America Genital Warts Treatment, by Country USD Million (2021-2026)
  • Table 207. North America Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 208. North America Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 209. North America Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 210. United States Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 211. United States Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 212. United States Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 213. Canada Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 214. Canada Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 215. Canada Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 216. Mexico Genital Warts Treatment, by Drug Type USD Million (2021-2026)
  • Table 217. Mexico Genital Warts Treatment, by Mechanism of Action USD Million (2021-2026)
  • Table 218. Mexico Genital Warts Treatment, by Stage USD Million (2021-2026)
  • Table 219. Research Programs/Design for This Report
  • Table 220. Key Data Information from Secondary Sources
  • Table 221. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genital Warts Treatment: by Drug Type USD Million (2015-2020)
  • Figure 5. Global Genital Warts Treatment: by Mechanism of Action USD Million (2015-2020)
  • Figure 6. Global Genital Warts Treatment: by Stage USD Million (2015-2020)
  • Figure 7. South America Genital Warts Treatment Share (%), by Country
  • Figure 8. Asia Pacific Genital Warts Treatment Share (%), by Country
  • Figure 9. Europe Genital Warts Treatment Share (%), by Country
  • Figure 10. MEA Genital Warts Treatment Share (%), by Country
  • Figure 11. North America Genital Warts Treatment Share (%), by Country
  • Figure 12. Global Genital Warts Treatment share by Players 2020 (%)
  • Figure 13. Global Genital Warts Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Genital Warts Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck & co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Merck & co. Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Teva Pharmaceuticals Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 19. Teva Pharmaceuticals Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 20. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer (United States) Revenue: by Geography 2020
  • Figure 22. Seqirus (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Seqirus (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 25. Sanofi (France) Revenue: by Geography 2020
  • Figure 26. Novan Inc (United States) Revenue, Net Income and Gross profit
  • Figure 27. Novan Inc (United States) Revenue: by Geography 2020
  • Figure 28. Mylan NV (United States) Revenue, Net Income and Gross profit
  • Figure 29. Mylan NV (United States) Revenue: by Geography 2020
  • Figure 30. Verrica Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Verrica Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 32. Aresus Pharma GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Aresus Pharma GmbH (Germany) Revenue: by Geography 2020
  • Figure 34. 3M (United States) Revenue, Net Income and Gross profit
  • Figure 35. 3M (United States) Revenue: by Geography 2020
  • Figure 36. Global Genital Warts Treatment: by Drug Type USD Million (2021-2026)
  • Figure 37. Global Genital Warts Treatment: by Mechanism of Action USD Million (2021-2026)
  • Figure 38. Global Genital Warts Treatment: by Stage USD Million (2021-2026)
  • Figure 39. South America Genital Warts Treatment Share (%), by Country
  • Figure 40. Asia Pacific Genital Warts Treatment Share (%), by Country
  • Figure 41. Europe Genital Warts Treatment Share (%), by Country
  • Figure 42. MEA Genital Warts Treatment Share (%), by Country
  • Figure 43. North America Genital Warts Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Merck & co. Inc. (United States)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Pfizer (United States)
  • Seqirus (United Kingdom)
  • Sanofi (France)
  • Novan Inc (United States)
  • Mylan NV (United States)
  • Verrica Pharmaceuticals (United States)
  • Aresus Pharma GmbH (Germany)
  • 3M (United States)
Additional players considered in the study are as follows:
Mayo Clinic (United States) , Torii Pharmaceutical (Japan) , Tamir Biotechnology (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation